Retinoic acid receptor beta (RARβ) and Retinoic acid receptor gamma (RARγ) (RARβ/γ)

Retinoic acid receptors (RARs) are ligand-dependent transcription factors belonging to the nuclear hormone receptor superfamily (UniProt: P10826, P13631). They exist in three distinct isoforms—alpha, beta, and gamma—which exhibit tissue-specific expression patterns and distinct biological roles (PubMed: 10423236). RARβ and RARγ are particularly significant in the context of epithelial biology and oncology; RARβ often functions as a tumor suppressor and is frequently silenced in various malignancies, while RARγ is the predominant isoform in the human epidermis (PubMed: 22503444). Therapeutic targeting of these specific isoforms is a cornerstone of dermatological treatment, where selective agonists like adapalene and tazarotene are used to treat acne and psoriasis by regulating keratinocyte differentiation and reducing inflammation (PubChem: CID 60164). Upon activation by retinoic acid or synthetic analogs, these receptors form heterodimers with Retinoid X Receptors (RXRs) to bind Retinoic Acid Response Elements (RAREs) in DNA, thereby controlling the expression of genes essential for cellular homeostasis and development (StatPearls: NBK541005).

Other names

NR1B2NR1B3Retinoic acid receptor betaRetinoic acid receptor gammaRAR-betaRAR-gammaRAR-beta/gamma

Agonists bind to the ligand-binding domain of RARβ and RARγ, inducing a conformational change that promotes heterodimerization with Retinoid X Receptors (RXR). This complex binds to Retinoic Acid Response Elements (RAREs) in the promoter regions of target genes, recruiting co-activators to modulate gene transcription involved in cell differentiation and proliferation (PubMed: 10423236).